Background: With increasing antibiotic usage Clostridium difficile colitis is becoming more common. Surgery for fulminating C. difficile colitis, however, is rare because of the effectiveness of specific anticlostridial chemotherapy. Surgical outcome in five patients with fulminating C. difficile colitis involved in a recent outbreak of this disease is reported.
Methods: Five of 138 patients developed fulminating C. difficile colitis unresponsive to medical therapy. All patients had antibiotics in the preceding period. Indications for operation in those who underwent surgery were systemic toxicity with a pyrexia, marked leukocytosis and abdominal signs leading to progressive organ failure, despite appropriate anticlostridial antibiotic therapy.
Results: At operation all patients had a markedly oedematous colon with normal serosa but with acute mucosal colitis. All underwent subtotal abdominal colectomy and ileostomy. Progressive organ failure persisted in four, leading to death, giving a mortality rate of four in five in the operated group in comparison with 3.8 per cent (five of 133 patients) in those treated medically.
Conclusions: These results indicate that this increasingly common disease frequently leads to a fatal outcome in patients requiring surgery and implies that earlier surgical consultation may be necessary to improve survival in patients with fulminating C. difficile colitis unresponsive to antibiotic therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1365-2168.1998.00519.x | DOI Listing |
The gastrointestinal microbiome influences physiological functions and is altered in a variety of diseases. The causality of "dysbiosis" in the pathogenesis is not always proven; association studies are often involved. Patients with IBD, bacteria, fungi, bacteriophages, and archaea show disease-typical patterns associated with metabolome disturbances.
View Article and Find Full Text PDFDtsch Med Wochenschr
February 2025
German surveillance data from 2022 reported a prevalence of nosocomial infections among hospitalized patients of 5,2%. Clostridioides-difficile-infections (CDI) are the most frequent cause of nosocomial diarrhea. They are usually caused by antibiotic exposure and the subsequent changes in the gut microbiota.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.
View Article and Find Full Text PDFJ Bacteriol
January 2025
Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
infection (CDI), characterized by colitis and diarrhea, afflicts approximately half a million people in the USA every year, burdening both individuals and the healthcare system. 630Δ is an erythromycin-sensitive variant of the clinical isolate 630 and is commonly used in the research community due to its genetic tractability. 630Δ possesses a point mutation in , an autoregulated transcriptional repressor that regulates oxidative stress resistance genes.
View Article and Find Full Text PDFCureus
December 2024
Pulmonary and Critical Care Medicine, Rutgers New Jersey Medical School University Hospital, Newark, USA.
Enteral administration of vancomycin is the standard treatment for () colitis and is presumed to have no systemic absorption. In critically ill patients, however, especially with multi-organ failure, enteral absorption of vancomycin is unpredictable and can cause severe toxicity if it remains unrecognized. We therefore report a case of systemic absorption of enteric vancomycin in a patient with severe colitis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!